Novo Nordisk says Ozempic a “very likely” target in next Medicare drug pricing talks
A top executive at Novo Nordisk (NVO) warned Tuesday that the company’s diabetes therapy Ozempic will likely be selected for the next round of Medicare drug pricing negotiations, which aim to seek discounts for blockbuster meds supplied to the federal healthcare program.
Novo Says Ozempic ‘Very Likely’ Target for Next US Price Cut
Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs targeted for a price cut in bargaining with the US government’s Medicare program, a company executive said.
Cheap Ozempic is coming: Cost could soon be slashed for millions of Americans, drugmaker confirms — here’s how
This news of Ozempic price cuts comes on the heels, or tablet, of Novo Nordisk developing a weight loss pill that mirrors the effects of Ozempic. According to new trial results, the pharmaceutical company says Amycretin can cause weight loss of up to 13% in three months.
Generic Ozempic could sell for less than $100. What's stopping its sale?
Americans are paying more than $900 a month for popular weight-loss drugs Ozempic and Wegovy, but drugmakers want to sell generic versions of the drugs for
Novo Nordisk expects Ozempic in next round of Medicare price talks
In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D for the first cycle of negotiations.
US Senator Sanders Says Generic Drugmakers Could Sell Ozempic for Less Than $100/month
U.S. Senator Bernie Sanders said on Tuesday he received confirmation from major generic pharmaceutical companies that they could sell copycat versions of Novo Nordisk's diabetes drug Ozempic for less than $100 a month.
Ozempic Could Soon Be Cheaper in US
Ozempic dose. The type 2 diabetes drug, which can also cause weight loss, may be about to get cheaper. Ozempic dose. The type 2 diabetes drug, which can also cause weight loss, ma
devdiscourse2d
Top Health News Briefs: Low-Cost Ozempic, FDA's Blindsight Tag, and More
The latest health news includes Sen. Sanders advocating for affordable Ozempic, Neuralink's FDA 'breakthrough' for Blindsight ...
STAT1d
Pharmalittle: We’re reading about pharma patent maneuvers, the U.S. warning J&J, and more
Some drugmakers' submission of multiple "use codes" to expand patent claims appears to be delaying the arrival of lower-cost ...
Ozempic ‘very likely’ to see prices slashed in drug price negotiations
The ability to negotiate drug prices is part of a sweeping set of policies in President Joe Biden’s Inflation Reduction Act.
Ozempic’s Price ‘Very Likely’ To Be Subject Of Medicare Negotiations, Report Says
President Joe Biden’s Inflation Reduction Act allows Medicare to negotiate costly drug prices with pharmaceutical companies.
Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.
Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports
Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of ...
Can Medicare Part D cover Ozempic?
Will Medicare Part D cover Ozempic? Read on to learn more about when Medicare may provide coverage for Ozempic or other ...